Fri, Aug 29, 2014, 11:26 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

ajetjock 50 posts  |  Last Activity: Aug 28, 2014 11:17 PM Member since: Mar 11, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ajetjock ajetjock Jul 9, 2014 12:48 PM Flag

    NOTHING has changed in regards to future catalysts with the pipeline waiting approval.

    They (IPCI)HAVE proven the concept.

    The only difference is that today, the shorts can sling all kind of MADE UP BS.

    Sentiment: Strong Buy

  • IPCI float is a MINIMAL 17M !

    TOTAL number of shares is also minimal at 23M.

    Go and check these numbers on ANY other pharma...

    Now, ALL pharma survive on issuing stock UNTIL they have enough revenue as a result of FDA approved products.

    This IS simply how the business operates, and it seems that SHORTS trying to pray on naive longs, use this fact against the longs in a campaign of FEAR. Same happens with almost ALL pharma.

    REALITY: As we see from the MINIMAL number of shares, IPCI has been VERY responsible and is NOT issuing too many shares.

    Another reality: INSIDERS own 40% of the shares ! Hence they too have the same interests as long investors : enhance shareholders value.

    I do not know of any other pharma but SNTA, where insiders are so heavily invested in the Co.

    Last...

    With multiple drugs in the pipline, and several pending practically ANY DAY, revenue WILL increase very likely this year.

    Smart investors buy EARLY.

    With the LOW FLOAT we have at IPCI, buying after the news, will cost you. As we have seen with previous approval the stock moved from less than 2 to 6.5 ...FAST.

    IGNORE the SHORTS ! Why would anyone hang around a stock they don't like ??? Unless they want YOU to fear and sell.

    Do YOUR OWN THINKING.

    Sentiment: Strong Buy

  • At May 31, 2014, Intellipharmaceutics' cash totaled $7.3 million, compared with $0.8 million at November 30, 2013.

    Sentiment: Strong Buy

  • Reply to

    What is the next catalyst?

    by hsangha56 Jul 7, 2014 2:36 PM
    ajetjock ajetjock Jul 7, 2014 10:52 PM Flag

    So aside from multiple patents and potential FDA approval, we also have the CEO search ongoing with potential announcement any time. I suspect that announcement to be another significant catalyst.
    Even thought the SNTA board is VERY talented and handles the company just fine.

    Sentiment: Strong Buy

  • Reply to

    Three ANDAs are Overdue

    by dr_c6 Jul 2, 2014 1:24 PM
    ajetjock ajetjock Jul 7, 2014 10:42 AM Flag

    Yep !

    Just sitting and waiting...

    Patience pays.

    Sentiment: Strong Buy

  • Reply to

    This is just the beginning folks.

    by ajetjock Jul 7, 2014 10:01 AM
    ajetjock ajetjock Jul 7, 2014 10:08 AM Flag

    From the Wall St. Cheatsheet article:

    Trading at measly $4.25 per share, Synta may be sitting on a drug that could generate billions in revenue and result in the stock moving magnitudes higher than current levels. Why wouldn’t Pfizer or another competitor step in and scoop it up? The purpose of Synta has a leading anti-cancer drug candidate, ganetespib, which is showing extreme promise. Ganetespib belongs to a new class of drugs known as heat shock protein 90 (Hsp 90) inhibitors. Hsp90 plays a role in the maturation of client proteins, which help cells growth, divide, and survive. Compared to healthy cells, cancer cells are more dependent on elevated levels of Hsp90 to proliferate. As such, inhibiting the production of Hsp90 could stop certain types of cancer. Unlike other targeted therapies that seek out specific mutations — like Pfizer’s Xalkori, which are specifically tailored to seek out and attack specific mutated cells — Hsp90 inhibitors are believed to be able to disrupt several signaling pathways simultaneously to stop tumor cell proliferation.

    Why am I so excited about this company? Well, the data is pretty convincing. Treatment with ganetespib has been shown in preclinical models to reduce some aggressive features of tumors, such as the ability to induce the growth of new blood vessels, the ability to spread to other organs in the body, and to resist attack by traditional therapies, such as chemo. Synta is primarily focusing on developing ganetespib as a treatment for non-small-cell lung cancer (or, NSCLC) breast cancer and colorectal cancer. If approved, the drug is expected to hit annual peak sales of $425 million to $600 million.

    Here is the one problem: While its anticancer properties are not in question, successful formulation of a drug that can actively treat cancer in patients is indeed in question. It has been tough to move from the biochemistry to the in vivo therapy. If you are looking for the one company with a real shot to get FDA approval

    Sentiment: Strong Buy

  • We have a long move UP ahead.

    Sentiment: Strong Buy

  • Reply to

    News

    by ziddox Jul 3, 2014 12:16 PM
    ajetjock ajetjock Jul 3, 2014 2:21 PM Flag

    As far as patents go. We all know this is NOT the first or only patent SNTA has.

    Does any of you keep a running total of their patents ? How many patents do they hold ?

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 2, 2014 1:18 PM Flag

    I agree.

    SNTA board is VERY talented and has the experience to prove it.

    They clearly know what they are doing.

    Just ask INCY shareholders for example.

    Sentiment: Strong Buy

  • They don't MANUFACTURE news to pump the price. Even though INSIDERS own 40% of IPCI.

    Once a company appears to be more in the stock PR business, REAL news gets lost and REAL investors lose interest.

    IPCI management acts *RESPONSIBLY* !

    The same applies to their line of credit via shelf registration. Contrary to Gregory's BS, they don't just print paper, its a CREDIT line to be available WHEN NEEDED ! (Excellent indicator.)

    Fact is: FLOAT is still MINIMAL and news will be MEANINGFUL, when arrive.

    Sentiment: Strong Buy

  • ajetjock ajetjock Jul 2, 2014 9:12 AM Flag

    Sadly....This "gross incompetence" version is about the only explanation that makes sense.

    I am wiling to guess it MAY have had to do with recent investment conf. they just had ?!

    Sentiment: Strong Buy

  • ajetjock by ajetjock Jun 30, 2014 10:59 AM Flag

    From Wiki:

    Fr history: 2008 Financial Crisis
    During the 2008 financial crisis Caxton Associates did not erect gates freezing investor capital in their Caxton Global Investments fund.[11] As reported the fund saw client redemptions totalling 27% of assets under management through 2008–2009—while returning 13% for the year.[11] The redemptions were reportedly born out of cash strapped clients many of whose asset allocations were gated and frozen at other investment management companies Caxton Associates is a global macro hedge fund founded by Bruce Kovner in 1983 and is headquartered in New York City.[1][3] The firm also has offices in London, Sydney, and Princeton, New Jersey. As a global macro hedge fund, Caxton Associates identifies investments according to their research of global markets and analysis of worldwide economic trends ...In 2008, Bruce Kovner stepped back from trading and appointed Andrew Law as Caxton’s Chief Investment Officer. In 2011, Law was appointed as the Chairman, CEO and controlling general partner of Caxton Associates, following the retirement of Kovner.[5] Law joined the London office in 2003 from Goldman Sachs, where he was Managing Director and head of FICC proprietary trading in London.[6]

    2008 Financial Crisis
    During the 2008 financial crisis Caxton Associates did not erect gates freezing investor capital in their Caxton Global Investments fund.[11] As reported the fund saw client redemptions totalling 27% of assets under management through 2008–2009—while returning 13% for the year.[11] The redemptions were reportedly born out of cash strapped clients many of whose asset allocations were gated and frozen at other investment management companies... In 2010 it was reported that since 1983 Caxton Associates had returned $12.8 billion to clients whilst managing $6 billion; ranking second amongst managers who have returned more than they currently manage.

    Sentiment: Strong Buy

  • Reply to

    Something is comming for sure.

    by maxwellsmart322 Jun 28, 2014 2:17 PM
    ajetjock ajetjock Jun 30, 2014 10:44 AM Flag

    I would also HIGHLY suggest investors Google / Wiki: Caxton !
    Caxton is HIGHLY invested in SNTA.

    READ about them !!!

    Sentiment: Strong Buy

  • Reply to

    Steven Bernitz - LinkedIN page

    by jdoobah Jun 28, 2014 12:27 PM
    ajetjock ajetjock Jun 30, 2014 10:19 AM Flag

    Could be...which IS a positive indicator for longs .

    Obviously insiders are seeking nice return on their investment ...and SOONER rather than later.

    Sentiment: Strong Buy

  • Reply to

    Steven Bernitz - LinkedIN page

    by jdoobah Jun 28, 2014 12:27 PM
    ajetjock ajetjock Jun 30, 2014 9:28 AM Flag

    Here is just ONE of their BOD members:

    Mr. Keith R. Gollust served as a Founding Partner at Gollust, Tierney and Oliver. Mr. Gollust serves as the Chairman of the Board at Synta Pharmaceuticals. He serves as the Chairman of the Advisory Council of the Princeton University Department of Astrophysics. Mr. Gollust serves as a Director of Archimedes Technology and The Juilliard School and a Member of the Advisory Board at Blackstone Alternative Asset Management. He serves as a Member of the Advisory Board at Aperture Venture Partners, LLC. He served as a Director at Mevion Medical Systems, Inc. since March 2008. Mr. Gollust is a graduate of Princeton University and the Carnegie Mellon School of Business Administration.

    Sentiment: Strong Buy

  • Reply to

    Steven Bernitz - LinkedIN page

    by jdoobah Jun 28, 2014 12:27 PM
    ajetjock ajetjock Jun 30, 2014 9:19 AM Flag

    FWIW:

    In recent investor presentation SNTA claims to have a very "strong" BOD and very capable of running the Co.

    Now, wasn't Bernitz brought in shortly prior to Safi's departure ?

    Could it be they are getting close to announce a CEO ?

    Either way, interesting development.

    Sentiment: Strong Buy

  • Always a good sign when shorts surface and are starting to post junk.
    On the flip side of shorty, another positive article out today.
    ...and the investment conf.
    The last SNTA meeting with investors resulted a positive move.
    Lets hope for more of the same.

    Sentiment: Strong Buy

  • Just waiting for next approval/s news.

    Patience will be rewarded.

    In spite of shorts utter BS, float is STILL MINIMAL, hence the move WILL be fast
    once news is out.

    So I am just waiting and enjoining Gregory and his aliases daily psychotics episode. Obviously most investors are smart enough to just ignore the noise.

    Sentiment: Strong Buy

  • Reply to

    CLUE ME IN PLEASE!! PLEASE!!

    by bruceogle2010 Jun 23, 2014 12:22 PM
    ajetjock ajetjock Jun 23, 2014 1:13 PM Flag

    The only reason I can see is If you want to ACCUMULATE and build a large position. Which would make sense as to why he is trying to keep the price depressed.

    Otherwise if you keep bidding up, this stock can move UP... FAST.

    Sentiment: Strong Buy

  • ajetjock by ajetjock Jun 19, 2014 9:14 PM Flag

    If you bother to call the Equity Group which represents SCOK in he US, you will realize that SCOK is a LEGIT Chinese Co. Not only they are legit, but over the years they avoided just issuing stock and have maintained their low float through the tough (for Coal) years.

    Back when Coal was hot commodity, SCOK was in the (are you sitting down ?) 40s PPS.

    They have worked hard on adjusting their business plan.

    I was glad to see the release today and it looks as if they are turning the corner as we speak.

    YES ! I bought more today.

    As a side note, aside from syn-gas China will still need various products of coal, SCOK is adaptive and WILL be there for the market.

    Sentiment: Strong Buy

SNTA
4.00-0.03(-0.74%)Aug 29 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.